Abstract:Bordetella bronchiseptica, a Gram-negative bacterium, causes chronic respiratory tract infections in a wide variety of mammalian hosts, including humans (albeit rarely). We recently designed Bordetella pertussis and Bordetella parapertussis experimental vaccines based on outer membrane vesicles (OMVs) derived from each pathogen, and we obtained protection against the respective infections in mice. Here, we demonstrated that OMVs derived from virulent-phase B. bronchiseptica (OMVBbvir+) protected mice against sublethal infections with different B. bronchiseptica strains, two isolated from farm animals and one isolated from a human patient. In all infections, we observed that the B. bronchiseptica loads were significantly reduced in the lungs of vaccinated animals; the lung-recovered CFU were decreased by ≥4 log units, compared with those detected in the lungs of nonimmunized animals (P < 0.001). In the OMVBbvir+-immunized mice, we detected IgG antibody titers against B. bronchiseptica whole-cell lysates, along with an immune serum having bacterial killing activity that both recognized B. bronchiseptica lipopolysaccharides and polypeptides such as GroEL and outer membrane protein C (OMPc) and demonstrated an essential protective capacity against B. bronchiseptica infection, as detected by passive in vivo transfer experiments. Stimulation of cultured splenocytes from immunized mice with OMVBbvir+ resulted in interleukin 5 (IL-5), gamma interferon (IFN-γ), and IL-17 production, indicating that the vesicles induced mixed Th2, Th1, and Th17 T-cell immune responses. We detected, by adoptive transfer assays, that spleen cells from OMVBbvir+-immunized mice also contributed to the observed protection against B. bronchiseptica infection. OMVs from avirulent-phase B. bronchiseptica and the resulting induced immune sera were also able to protect mice against B. bronchiseptica infection.IMPORTANCEBordetella bronchiseptica, a Gram-negative bacterium, causes chronic respiratory tract infections in a wide variety of mammalian hosts, including humans (albeit rarely). Several vaccines aimed at preventing B. bronchiseptica infection have been developed and used, but a safe effective vaccine is still needed. The significance and relevance of our research lie in the characterization of the OMVs derived from B. bronchiseptica as the source of a new experimental vaccine. We demonstrated here that our formulation based on OMVs derived from virulent-phase B. bronchiseptica (OMVBbvir+) was effective against infections caused by B. bronchiseptica isolates obtained from different hosts (farm animals and a human patient). In vitro and in vivo characterization of humoral and cellular immune responses induced by the OMVBbvir+ vaccine enabled a better understanding of the mechanism of protection necessary to control B. bronchiseptica infection. Here we also demonstrated that OMVs derived from B. bronchiseptica in the avirulent phase and the corresponding induced humoral immune response were able to protect mice from B. bronchiseptica infection. This realization provides the basis for the development of novel vaccines not only against the acute stages of the disease but also against stages of the disease or the infectious cycle in which avirulence factors could play a role.

Two Bordetella Bronchiseptica Attenuated Vaccine Candidates Confer Protection Against Lethal Challenge with B. Bronchiseptica and Pasteurella Multocida Toxin in Mouse Models.

Immunogenicity and Protective Efficacy of a Multi-Epitope Recombinant Toxin Antigen of Pasteurella Multocida Against Virulent Challenge in Mice.

Immunogenicity of Recombinant Protective Antigen and Efficacy Against Intranasal Challenge with Bordetella Bronchiseptica

Membrane Vesicles Derived from Bordetella bronchiseptica: Active Constituent of a New Vaccine against Infections Caused by This Pathogen

[Protecting Mice from Fatal Bordetella Bronchiseptica Infection by Immunization with Recombinant Pertactin Antigens].

[Characteristics and Immunogenicity of the N-terminal and C-terminal Recombinants of Pasteurella Multocida Toxin].

[Immunogenicity and Protective Efficacy of Pertactin Recombinants Against Bordetella Bronchiseptica Challenge].

Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines

Attenuated vaccine PmCQ2Δ4555-4580 effectively protects mice against Pasteurella multocida infection

A Marker-Free Bordetella bronchiseptica aroA/ bscN Double Deleted Mutant Confers Protection Against Lethal Challenge

Protection Elicited by Nasal Immunization with Pneumococcal Surface Protein A (pspa) Adjuvanted with Bacterium-Like Particles Against Streptococcus Pneumoniae Infection in Mice

Virus-like particles displaying the mature C-terminal domain of filamentous hemagglutinin are immunogenic and protective against Bordetella pertussis respiratory infection in mice

Immunogenicity of Recombinant R1 Region Antigen of Pertactin and Its Efficacy Against Bordetella Bronchiseptica Challenge

Subcutaneous Vaccination With Attenuated Salmonella Enterica Serovar Choleraesuis C500 Expressing Recombinant Filamentous Hemagglutinin And Pertactin Antigens Protects Mice Against Fatal Infections With Both S-Enterica Serovar Choleraesuis And Bordetella Bronchiseptica

Protection of Mice with a Divalent Tuberculosis DNA Vaccine Encoding Antigens Ag85B and MPT64

T-B cell epitope peptides induce protective immunity against Mycoplasma pneumoniae respiratory tract infection in BALB/c mice

Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice

Recombinant Pseudomonas Bionanoparticles Induce Protection against Pneumonic Pseudomonas aeruginosa Infection

Aerosolized Intratracheal Inoculation of Recombinant Protective Antigen (rPA) Vaccine Provides Protection Against Inhalational Anthrax in B10.D2-Hc0 Mice

Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice

A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice